Printer Friendly

BIOSPECIFICS TECHNOLOGIES EXPLORES LICENSING OF PHARMACEUTICAL PRODUCTS TO IVAX

 BIOSPECIFICS TECHNOLOGIES EXPLORES LICENSING
 OF PHARMACEUTICAL PRODUCTS TO IVAX
 LYNBROOK, N.Y., May 19 /PRNewswire/ -- Biospecifics Technologies Corp. (NASDAQ: BSTC) announced today that it is exploring the licensing of a number of its pharmaceutical products to Ivax for distribution in the United States and overseas.
 BSTC emphasized that these discussions are preliminary and continuing.
 -0- 5/19/92
 /CONTACT: Edwin Wegman, chairman and president of Biospecifics Technologies, 516-593-7000/
 (BSTC) CO: Biospecifics Technologies Corp. ST: Massachusetts IN: MTC SU: LIC


PS -- NY030 -- 1707 05/19/92 10:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:88
Previous Article:GOLD JEWELRY FABRICATION INCREASES 4 PERCENT TO A NEW RECORD; GOLD MINE PRODUCTION GROWTH SLOWS TO 2 PERCENT -- LOWEST IN THE PAST DECADE
Next Article:VANTAGE POINT AND CONVEST SIGN AGREEMENT
Topics:


Related Articles
BAKER CUMMINS PHARMACEUTICALS RECEIVES LICENSE TO CHEMOPROTECTIVE DRUG
BIOSPECIFICS TECHNOLOGIES ANNOUNCES FIRST QUARTER FISCAL 1993 RESULTS
BIOSPECIFICS ANNOUNCES EXPANSION OF CLINICAL TRIALS FOR OINTMENT
BIOSPECIFICS TECHNOLOGIES ANNOUNCES FOURTH QUARTER AND YEAR-END RESULTS
BAKER NORTON PHARMACEUTICALS RECEIVES LICENSE FROM RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT BUFFALO FOR NEW VASODILATOR THERAPY
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES FIRST QUARTER FISCAL 1994 RESULTS
BIOSPECIFICS TECHNOLOGIES CORP. LICENSEE RECEIVES MARKETING APPROVAL OF COLLAGENASE OINTMENT IN INDIA
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES COLLAGENASE OINTMENT CONTRACT IN ITALY
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES COLLAGENASE OINTMENT LICENSE AGREEMENT IN GERMANY
BioSpecifics Announces Partnership Between Pfizer and Auxilium for XIAFLEX(TM) in Europe.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters